

**Supplemental Materials for:**

**Reduced magnitude and durability of humoral immune responses by COVID-19 mRNA vaccines among older adults**

Mark A. Brockman<sup>1,2,3,#,\*</sup>, Francis Mwimanzi<sup>1</sup>, Hope R. Lapointe<sup>3</sup>, Yurou Sang<sup>1</sup>, Olga Agafitei<sup>1</sup>, Peter Cheung<sup>1,3</sup>, Siobhan Ennis<sup>1</sup>, Kurtis Ng<sup>1</sup>, Simran Basra<sup>1,2,4</sup>, Li Yi Lim<sup>1,2</sup>, Fatima Yaseen<sup>2</sup>, Landon Young<sup>5</sup>, Gisele Umviligihozo<sup>1</sup>, F. Harrison Omondi<sup>1,3</sup>, Rebecca Kalikawe<sup>1</sup>, Laura Burns<sup>5</sup>, Chanson J. Brumme<sup>3,6</sup>, Victor Leung<sup>5,8</sup>, Julio S.G. Montaner<sup>3,6</sup>, Daniel Holmes<sup>7,8</sup>, Mari DeMarco<sup>7,8</sup>, Janet Simons<sup>7,8</sup>, Ralph Pantophlet<sup>1,2</sup>, Masahiro Niikura<sup>1</sup>, Marc G. Romney<sup>5,8,#,\*</sup>, Zabrina L. Brumme<sup>1,3,#,\*</sup>

<sup>1</sup> Faculty of Health Sciences, Simon Fraser University, Burnaby BC, Canada;

<sup>2</sup> Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby BC, Canada;

<sup>3</sup> British Columbia Centre for Excellence in HIV/AIDS, Vancouver BC, Canada;

<sup>4</sup> Department of Chemistry, Simon Fraser University, Burnaby BC, Canada;

<sup>5</sup> Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver BC, Canada;

<sup>6</sup> Department of Medicine, University of British Columbia, Vancouver BC, Canada;

<sup>7</sup> Division of Medical Biochemistry, St. Paul's Hospital, Vancouver BC, Canada;

<sup>8</sup> Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada

\*equal contribution


# Address correspondence to: MAB (mark\_brockman@sfu.ca); MGR

(mromney@providencehealth.bc.ca); or ZLB (zbrumme@sfu.ca)

**Supplemental Table 1. Multivariable Analyses (Roche Elecsys)**

Immunogenicity outcome	Variable	Time point			
		1 month after 1st dose		1 month after 2nd dose	
		$\beta$ estimate (95% CI)	p	$\beta$ estimate (95% CI)	p
Log10 RBD Total Ig	Age	-0.0087 (-0.015 to -0.0024)	<b>0.007</b>	-0.0073(-0.013 to -0.0019)	<b>0.009</b>
	Male Sex	-0.10 (-0.23 to 0.21)	0.9	0.026 (-0.16 to 0.21)	0.8
	White ethnicity	-0.049 (-0.27 to 0.17)	0.7	0.15 (-0.036 to 0.34)	0.1
	# Chronic health conditions	-0.14 (-0.23 to -0.043)	<b>0.005</b>	-0.12 (-0.21 to -0.042)	<b>0.003</b>
	Moderna vaccine (vs. Pfizer)	-0.23 (-0.67 to 0.19)	0.3	0.19 (-0.15 to 0.53)	0.3
	Days after vaccine dose	-0.0022 (-0.041 to 0.037)	0.9	0.015 (-0.020 to 0.050)	0.4


CI, confidence interval



**Supplemental Figure 1: Impact of second vaccine dose on immune responses.**

**Supplemental Figure 1: Impact of second vaccine dose on immune responses.** *Panel A:*

Increase in log<sub>10</sub> binding IgG antibody responses to RBD in plasma after the second vaccine dose, measured by Luminex ELISA, in HCW (blue circles) and Seniors+LTC (orange circles) who were COVID-19 naive at study entry. Bars represent median and IQR. P-value computed using the Mann-Whitney U-test. *Panel B:* Same data as A, but plotted by age. Statistics and linear model (red line) computed using ordinary least-squares regression. *Panel C:* Increase in ACE2-displacement function of vaccine-induced antibodies after the second dose, in the same participants. *Panel D:* Same data as C, but plotted by age. *Panel E:* Fold-increase in viral neutralization ability of vaccine-induced antibodies after the second dose in a subset of participants who were COVID-19 naive at study entry. *Panel F:* same data as E, but plotted by age.



**Supplemental Figure 2: Binding antibody responses to RBD following first and second vaccine doses, measured using a commercial assay.**

**Supplemental Figure 2: Binding antibody responses to RBD following first and second**

**vaccine doses, measured using a commercial assay. *Panel A:*** Spearman's correlation between

RBD IgG responses measured in plasma by Luminex ELISA and total antibody responses measured in serum using the Roche Elecsys SARS-CoV-2 S assay. ULOQ = Upper limit of quantification in the Roche assay, which was >25,000 U/mL; 11 samples had measurements above this limit. *Panel B:* Binding antibody responses to the RBD as measured by the Roche

assay following one vaccine dose in HCW (blue circles) and Seniors+LTC (orange circles) who were COVID-19 naive at study entry, and COVID-19 convalescent participants (Conv; colored as above). Bars represent median and IQR. P-values computed using the Mann-Whitney U-test. LLOD = Assay lower limit of detection. *Panel C:* Same data as the HCW and Seniors+LTC

groups shown in panel B, but plotted by age. Statistics and linear model (red line) computed using ordinary least-squares regression. *Panels D and E:* same as B and C, but after two doses of

mRNA vaccine. *Panel E:* Binding antibody responses as measured by the Roche assay, one month following the 2nd vaccine dose (Peak) and three months after this dose (3 months) in a

subset of HCW (blue circles) and individuals living in long-term care or assisted living facilities (LTC; orange) who were COVID-19 naive at study entry. P-values computed using the

Wilcoxon paired test.